

30th July, 2020

The Dy. General Manager (Listing Dept.) BSE Limited, Corporate Relationship Dept., 1st Floor, New Trading Ring, P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

(BSE Scrip Code: 500420)

The Manager – Listing Dept., National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G. Block, Bandra - Kurla Complex, Bandra (E), Mumbai – 400 051

(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Re: Proceedings of 47th Annual General Meeting of the Company held on 30th July, 2020

In terms of Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), we hereby inform you that the following business was transacted at the 47th Annual General Meeting (AGM) of the Company held through Video Conferencing (VC) / Other Audio Visual Means (OAVM) on 30th July, 2020:

- 1. Approval and adoption of Standalone and Consolidated Financial Statements as at 31st March, 2020, including the Audited Balance Sheet as at 31st March, 2020, the Statement of Profit and Loss for the year ended on that date and reports of the Board of Directors and Auditors thereon.
- 2. Confirmation of payment of interim dividend of ₹ 32.00 per equity share of fully paid up face value of ₹ 5.00 each, which included a special dividend of ₹ 15.00 per equity share, declared and distributed by the Board of Directors for the financial year ended on 31st March, 2020.
- 3. Re-appointment of a Director in place of Dr. Chaitanya Dutt (holding DIN 00110312), Director, who retires by rotation and being eligible, offers himself for re-appointment.
- 4. Ratification of remuneration of cost auditors of the company for the year 2020-21.
- 5. Payment of Commission to Sudhir Mehta, Chairman Emeritus for the year 2019-20.

The above business was transacted by Remote e-voting and e-voting at the meeting as required under Companies Act, 2013, Listing Regulations and MCA circular dated 5th May, 2020 read with circulars dated 8th April, 2020 and 13th April, 2020. Results of the passing of above resolutions as required under Regulation 44(3) of Listing Regulations will be disclosed to the Stock Exchange separately.

Kindly take note of the above.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL VP (LEGAL) & COMPANY SECRETARY